Genital Diseases, Female  >>  Cetrotide (cetrorelix)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cetrotide (cetrorelix) / EMD Serono
NCT01079949 / 2006-005268-19: A Phase II Study to Assess the Efficacy and Safety of Luveris® (Lutropin Alfa) in Mid Follicular Phase for Controlled Ovarian Stimulation (COS) in Advanced Reproductive Age

Terminated
2
93
Europe
r-hLH + r-hFSH, Luveris®, Lutropin alfa, r-hFSH, Recombinant Human Choriogonadotropin (r-hCG), Ovitrelle®, GnRH antagonist, Cetrotide®
Merck KGaA, Darmstadt, Germany, Merck, S.L., Spain
Infertility, Ovulation Induction
10/10
10/10
NCT01204840: Growth Hormone for Poor Responders in in Vitro Fertilization (IVF)

Completed
2
38
Canada
Growth Hormone, Saizen (Somatoptropin; Human growth hormone), Patch protocol
Ottawa Fertility Centre, EMD Serono
Infertility, Poor Ovarian Reserve
05/15
05/15
NCT02784457: Gonadotropin Releasing Hormone Antagonist in Treatment of Early-onset Severe Ovarian Hyperstimulation Syndrome

Completed
2
84
RoW
Cetrorelix
Ain Shams University
Assisted Reproduction
12/15
03/16
NCT01109888: Administration of Increased Dose of GnRH Antagonist for Coasting for Decreasing the Risk for Ovarian Hyperstimulation Syndrome( OHSS)

Withdrawn
1/2
0
RoW
Cetrotide
Wolfson Medical Center
Administration of Increased Dose of GnRH Antagonist for Coasting for Decreasing the Risk for Ovarian Hyperstimulation Syndrome( OHSS)
 
 

Download Options